Kristin M D'Silva1,2,3, Zachary S Wallace1,2,3. 1. Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital. 2. Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital. 3. Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, drug shortages, limited access to care, social isolation, and mental health. This review will examine the multifaceted impacts of the COVID-19 pandemic on patients living with RA. RECENT FINDINGS: In patients with RA, risk factors for severe COVID-19 outcomes include older age and comorbidities, similar to those in the general population. Glucocorticoids, but not other classes of disease-modifying antirheumatic drugs (DMARDs), appear to be associated with a higher risk of severe COVID-19 outcomes. RA patients have been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which may contribute to disease flares. SUMMARY: Glucocorticoids, but not other DMARDs, are associated with a higher risk of severe COVID-19 outcomes in RA patients. Further studies are needed to explore the impact of specific DMARDs on COVID-19 outcomes, understand the broader implications of the COVID-19 pandemic on RA disease activity, and optimize the use of telemedicine in RA management.
PURPOSE OF REVIEW: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, drug shortages, limited access to care, social isolation, and mental health. This review will examine the multifaceted impacts of the COVID-19 pandemic on patients living with RA. RECENT FINDINGS: In patients with RA, risk factors for severe COVID-19 outcomes include older age and comorbidities, similar to those in the general population. Glucocorticoids, but not other classes of disease-modifying antirheumatic drugs (DMARDs), appear to be associated with a higher risk of severe COVID-19 outcomes. RA patients have been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which may contribute to disease flares. SUMMARY: Glucocorticoids, but not other DMARDs, are associated with a higher risk of severe COVID-19 outcomes in RA patients. Further studies are needed to explore the impact of specific DMARDs on COVID-19 outcomes, understand the broader implications of the COVID-19 pandemic on RA disease activity, and optimize the use of telemedicine in RA management.
Authors: Ted R Mikuls; Sindhu R Johnson; Liana Fraenkel; Reuben J Arasaratnam; Lindsey R Baden; Bonnie L Bermas; Winn Chatham; Stanley Cohen; Karen Costenbader; Ellen M Gravallese; Andre C Kalil; Michael E Weinblatt; Kevin Winthrop; Amy S Mudano; Amy Turner; Kenneth G Saag Journal: Arthritis Rheumatol Date: 2020-07-30 Impact factor: 10.995
Authors: Rebecca Haberman; Jordan Axelrad; Alan Chen; Rochelle Castillo; Di Yan; Peter Izmirly; Andrea Neimann; Samrachana Adhikari; David Hudesman; Jose U Scher Journal: N Engl J Med Date: 2020-04-29 Impact factor: 91.245
Authors: Bryant R England; Claire E H Barber; Martin Bergman; Veena K Ranganath; Lisa G Suter; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2021-12 Impact factor: 5.178
Authors: Emily Sirotich; Sarah Dillingham; Rebecca Grainger; Jonathan S Hausmann Journal: Arthritis Care Res (Hoboken) Date: 2020-07 Impact factor: 5.178
Authors: Lu Lu; Le-Ping Liu; Rong Gui; Hang Dong; Yan-Rong Su; Xiong-Hui Zhou; Feng-Xia Liu Journal: Front Immunol Date: 2022-08-31 Impact factor: 8.786
Authors: Roxanne Cooksey; Jonathan Underwood; Sinead Brophy; Mark Atkinson; Jonathan Kennedy; Ernest Choy Journal: Rheumatology (Oxford) Date: 2022-06-28 Impact factor: 7.046